Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

By sjmartinez • December 13, 2024

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 9:S2352-3018(24)00247-9. doi: 10.1016/S2352-3018(24)00247-9. Epub ahead of print. PMID: 39667379.

Tags: Infectious Diseases, Publications

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands

Nerguizian D, Wei Z, Aldrovandi G, Currier J, Eron J, Fischer W, Gandhi R, Hamill M, Hosey L, Javan A, McCarthy C, Nachman S, Valiyaparambil[...]

Histone deacetylase 7 mediates lipopolysaccharide-inducible mitochondrial fission in macrophages

Abrol R, Afroz SF, Curson JEB, Raven KD, Gupta KD, Gunther KS, Jones A, Reid RC, Xiong Z, Gunter JH, Engel JA, Engwerda CR, Blumenthal[...]

Patterns of sexual minority men’s lifestyle and healthcare related activity spaces in Los Angeles

Cassels S, Reid SC, Murray AT, Kaloper S, Wang V, Shoptaw S, Gorbach P. Patterns of sexual minority men's lifestyle and healthcare related activity spaces[...]